DNDN : NASDAQ
Industry: Biotechnology

COMPANY PROFILE

Company Details

Dendreon Corporation. The Company's principal activities are to discover and develop novel products for the treatment of diseases through innovative manipulation of the immune system. It's product pipeline is focused on treatment of cancer and includes therapeutic vaccines, monoclonal antibodies, small molecules and pro-drugs. It's product Provenge, ... More
Shares Outstanding 115.9M
Institutional Ownership 58.27%
Market Cap 3.2B
Last Stock Split None None
Dr. Mitchell H. Gold Corporate Officer Address: 3005 First Avenue,Seattle,WASHINGTON 98121 www.dendreon.com

Investment Ratings

DNDN Highlights

First Call expects -0.29 EPS for next quarter.
The current Price Target for DNDN is $34.13.


COMPANY PERFORMANCE

Pricing Momentum
27.54
Last
0.47-1.68%
Today’s Change
28.30
Today’s Open
$28.39
Day High
$27.31
Day Low
--
Volume 
Quotes delayed by at least 20 minutes

Growth Rates

Earnings per Share

Revenue

Dividend


DNDN  IndustryMouse over chart for more details

Loading...
Loading...